{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n BRD9 is a multifunctional bromodomain‐containing protein that serves as an epigenetic reader and a critical component of noncanonical SWI/SNF (ncBAF) chromatin remodeling complexes. Structural and biochemical studies have shown that its bromodomain exhibits a degree of binding plasticity toward various acylated lysine marks—including longer acyl modifications—which expands the repertoire of chromatin signals it can interpret."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Within embryonic stem cells and other developmental contexts, BRD9‐containing complexes are recruited to discrete genomic regions—often via interactions with partners such as BRD4—thereby modulating transcriptional programs that sustain pluripotency and proper cell identity."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In the context of oncogenesis, BRD9 has emerged as a pivotal regulatory node in several malignancies. In synovial sarcoma, for example, BRD9 integrates into oncogenic SS18–SSX‐containing BAF complexes where its bromodomain is essential for maintaining aberrant transcriptional programs that drive tumor cell survival."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": " Similarly, in pediatric malignant rhabdoid tumors, a unique BRD9‐containing SWI/SNF subcomplex—lacking the normally core component SMARCB1—is critical for cell viability, with domains outside the bromodomain mediating complex integrity."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Beyond these tumor types, BRD9 is also implicated in other cancers. In squamous cell lung cancer, for instance, miR‐140–3p targets BRD9 leading to downregulation of oncogenic drivers such as c‐myc, whereas in ovarian cancer BRD9’s bromodomain binds acetylated substrates (e.g., RAD54) to facilitate proper RAD54–RAD51 interactions that are essential for homologous recombination repair; perturbation of this function sensitizes cancer cells to DNA‐damaging agents."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Additional studies in acute myeloid leukemia have identified BRD9 as overexpressed and functionally indispensable, supporting its candidacy as a therapeutic target; similar oncogenic roles—often involving modulation of pathways such as Notch signaling—have been described in prostate cancer and in subsets of clear cell renal cell carcinoma that lack HIF‐2α expression."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "8", "end_ref": "10"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Collectively, these findings delineate BRD9 as a key regulator at the interface of chromatin remodeling, transcriptional control, and DNA repair. Its multifaceted roles across normal developmental processes and a broad spectrum of cancers highlight the therapeutic potential of strategies aimed at its inhibition or targeted degradation."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}, {"type": "fg_fs", "start_ref": "3", "end_ref": "7"}, {"type": "fg_f", "ref": "2"}, {"type": "fg_fs", "start_ref": "8", "end_ref": "10"}]}, {"type": "t", "text": "\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "E Megan Flynn, Oscar W Huang, Florence Poy, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Structure (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.str.2015.08.004"}], "href": "https://doi.org/10.1016/j.str.2015.08.004"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26365797"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26365797"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Samantha M Bevill, Jose F Olivares-Quintero, Noah Sciaky, et al. "}, {"type": "b", "children": [{"type": "t", "text": "GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Cancer Res (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1541-7786.MCR-18-1121"}], "href": "https://doi.org/10.1158/1541-7786.MCR-18-1121"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31000582"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31000582"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Jovylyn Gatchalian, Shivani Malik, Josephine Ho, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Commun (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41467-018-07528-9"}], "href": "https://doi.org/10.1038/s41467-018-07528-9"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30510198"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30510198"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Gerard L Brien, David Remillard, Junwei Shi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Elife (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.7554/eLife.41305"}], "href": "https://doi.org/10.7554/eLife.41305"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30431433"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30431433"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Xiaofeng Wang, Su Wang, Emma C Troisi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Commun (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41467-019-09891-7"}], "href": "https://doi.org/10.1038/s41467-019-09891-7"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31015438"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31015438"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Haitao Huang, Yuxuan Wang, Qin Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Lett (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.canlet.2019.01.007"}], "href": "https://doi.org/10.1016/j.canlet.2019.01.007"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30660651"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30660651"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Qin Zhou, Jinzhou Huang, Chao Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Commun (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41467-020-16443-x"}], "href": "https://doi.org/10.1038/s41467-020-16443-x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32457312"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32457312"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Nunzio Del Gaudio, Antonella Di Costanzo, Ning Qing Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Death Dis (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41419-019-1570-9"}], "href": "https://doi.org/10.1038/s41419-019-1570-9"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31000698"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31000698"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Xiaoxian Sima, Jiangnan He, Jie Peng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS One (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pone.0222305"}], "href": "https://doi.org/10.1371/journal.pone.0222305"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31504061"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31504061"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Weijuan Lou, Ke Gao, Chenyue Xu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Bromodomain-containing protein 9 is a prognostic biomarker associated with immune infiltrates and promotes tumor malignancy through activating notch signaling pathway in negative HIF-2α clear cell renal cell carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "IUBMB Life (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/iub.2547"}], "href": "https://doi.org/10.1002/iub.2547"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34415102"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34415102"}]}]}]}